MSI-H

About

Biomarker Type: Microsatellite Stability

Present: True

Status: Microsatellite instability-high (MSI-H)


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) MSI-H Any solid tumor Pembrolizumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab
Sensitivity (+) MSI-H Endometrial Carcinoma Pembrolizumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Nivolumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (+) MSI-H Endometrial Carcinoma Dostarlimab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab
Sensitivity (+) MSI-H Endometrial Carcinoma Pembrolizumab
Sensitivity (+) MSI-H Esophagogastric Adenocarcinoma Pembrolizumab
Sensitivity (+) MSI-H Gastrointestinal Stromal Tumor Pembrolizumab
Sensitivity (+) MSI-H Cholangiocarcinoma Pembrolizumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab
Sensitivity (+) MSI-H Colorectal Adenocarcinoma Pembrolizumab